ArticleScientific reports2019
Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Physical and Chemical Methods for DNA Vaccine Delivery: Insights into the Melanoma Landscape.Molecular biotechnology · 2026Review
- Evaluation of Immunoprotective Effects of DNA Vaccine Based onAnimals : an open access journal from MDPI · 2026Article
- Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity.The Journal of pharmacology and experimental therapeutics · 2025Review
- Advancement insights in cancer vaccines: mechanisms, types, and clinical applications.Molecular biology reports · 2025Review
- The multifaceted role of XCL1 in health and disease.Protein science : a publication of the Protein Society · 2025Review
- Article
- Id-neoantigen vaccine induces therapeutic CD8Journal for immunotherapy of cancer · 2023Article
- Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine.Frontiers in immunology · 2023Article
- Cell-targeted vaccines: implications for adaptive immunity.Frontiers in immunology · 2023Review
- Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.Journal for immunotherapy of cancer · 2022Article
- Cancer vaccines as promising immuno-therapeutics: platforms and current progress.Journal of hematology & oncology · 2022Review
- Targeting Xcr1 on Dendritic Cells Rapidly Induce Th1-Associated Immune Responses That Contribute to Protection Against Influenza Infection.Frontiers in immunology · 2022Article
- Therapeutic cancer vaccines.Nature reviews. Cancer · 2021Review
- Review
- Co-Opting Host Receptors for Targeted Delivery of Bioconjugates-From Drugs to Bugs.Molecules (Basel, Switzerland) · 2021Review
- A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza.Molecular therapy. Methods & clinical development · 2020Article
- Autotransporter-Mediated Display of Complement Receptor Ligands by Gram-Negative Bacteria Increases Antibody Responses and Limits Disease Severity.Pathogens (Basel, Switzerland) · 2020Article
- DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy.Frontiers in pharmacology · 2019Review
- Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses.Frontiers in immunology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusing antigens to chemokines to target antigen presenting cells (APC) is a promising method for enhancing immunogenicity of DNA vaccines. However, it is unclear how different chemokines compare in terms of immune potentiating effects. Here we compare Ccl3- and Xcl1-fusion vaccines containing hemagglutinin (HA) from influenza A delivered by intramuscular (i.m.) or intradermal (i.d.) DNA vaccination. Xcl1 fusion vaccines target cDC1s, and enhance proliferation of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.